vTv Therapeutics (VTVT) vs. Its Competitors Head-To-Head Survey

vTv Therapeutics (NASDAQ:VTVT) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare vTv Therapeutics to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations.

Volatility & Risk

vTv Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, vTv Therapeutics’ peers have a beta of -3.81, indicating that their average stock price is 481% less volatile than the S&P 500.

Profitability

This table compares vTv Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-10.15%	-8.65%
vTv Therapeutics Competitors	-2,380.61%	-219.90%	-15.56%

Analyst Ratings

This is a breakdown of recent ratings for vTv Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1	1	6	1	2.78
vTv Therapeutics Competitors	7776	13772	25741	1037	2.41

vTv Therapeutics presently has a consensus target price of $55.83, suggesting a potential upside of 157.71%. As a group, “Pharmaceuticals” companies have a potential upside of 24.85%. Given vTv Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe vTv Therapeutics is more favorable than its peers.

Valuation & Earnings

This table compares vTv Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
vTv Therapeutics	$36.84 million	-$26.97 million	-23.55
vTv Therapeutics Competitors	$3.57 billion	$3.20 billion	552.49

vTv Therapeutics’ peers have higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

vTv Therapeutics beats its peers on 8 of the 13 factors compared.

About vTv Therapeutics

vTv Therapeutics Inc. (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs. Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.